The use of rituximab and bendamustine in treating chronic lymphocytic leukaemia (CLL) in end-stage renal disease (ESRD)

A patient with a history of type 2 diabetes mellitus and chronic lymphocytic leukaemia has renal failure with large kidneys. The patient refused kidney biopsy to determine the aetiology of her renal failure. She uses peritoneal dialysis to treat renal failure. She received rituximab and bendamustine...

Full description

Saved in:
Bibliographic Details
Published in:BMJ case reports 2013-05, Vol.2013, p.bcr2013009637
Main Authors: Shoji, Jun, Lew, Susie Q
Format: Article
Language:English
Subjects:
Abdomen
Antibodies, Monoclonal, Murine-Derived - therapeutic use
Antineoplastic Agents - therapeutic use
Bendamustine Hydrochloride
Black
Bone marrow
Chemotherapy
Diabetes
Diabetes Mellitus, Type 2 - complications
Electrolytes
Female
Humans
Kidney - pathology
Kidney diseases
Kidney Failure, Chronic - drug therapy
Kidney Failure, Chronic - etiology
Kidney Failure, Chronic - therapy
Leukemia, Lymphocytic, Chronic, B-Cell - complications
Leukemia, Lymphocytic, Chronic, B-Cell - drug therapy
Lymphatic system
Lymphocytes
Middle Aged
Nitrogen Mustard Compounds - therapeutic use
Novel Treatment (New Drug/Intervention
Established Drug/Procedure in New Situation)
Peritoneal Dialysis
Rituximab
USA/Canada
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:A patient with a history of type 2 diabetes mellitus and chronic lymphocytic leukaemia has renal failure with large kidneys. The patient refused kidney biopsy to determine the aetiology of her renal failure. She uses peritoneal dialysis to treat renal failure. She received rituximab and bendamustine to treat chronic lymphocytic leukaemia. Adenopathy resolves with treatment and she does not experience any electrolyte disturbances or decrease in urine output as a result of chemotherapy in the setting of renal failure. Renal function did not recover with chemotherapy.
ISSN:1757-790X
1757-790X
DOI:10.1136/bcr-2013-009637